Upstream Bio receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | UPB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipUPBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | −0.8x | −0.3x | |
PEG Ratio | −0.26 | −0.02 | 0.00 | |
Price/Book | 0.7x | 2.8x | 2.6x | |
Price / LTM Sales | 58.4x | 13.3x | 2.9x | |
Upside (Analyst Target) | - | 94.5% | 64.3% | |
Fair Value Upside | Unlock | 18.4% | 9.9% | Unlock |
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.